Liraglutide: A Review of Its Use in the Management of Obesity

Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients

(2014) Chun-Jun Li et al.   Cardiovascular Diabetology

Managing Overweight and Obesity in Adults to Reduce Cardiovascular Disease Risk

(2014) Jon O. Ebbert et al.   Current Atherosclerosis Reports

Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus

(2014) Lesley J. Scott   DRUGS

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Therapies for inter-relating diabetes and obesity – GLP-1 and obesity

(2014) Eva W Iepsen et al.   EXPERT OPINION ON PHARMACOTHERAPY

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

(2014) Anna Secher et al.   JOURNAL OF CLINICAL INVESTIGATION

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

GLP-1: benefits beyond pancreas

(2014) G. Muscogiuri et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

(2013) S. Madsbad   DIABETES OBESITY & METABOLISM

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

(2013) J van Can et al.   INTERNATIONAL JOURNAL OF OBESITY

Incretin hormones and the satiation signal

(2013) J J Holst   INTERNATIONAL JOURNAL OF OBESITY

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

(2013) T A Wadden et al.   INTERNATIONAL JOURNAL OF OBESITY

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

(2013) Michael D. Jensen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Why do we need drugs to treat the patient with obesity?

(2013) George A. Bray   Obesity

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes

(2012) Yuya Fujishima et al.   Cardiovascular Diabetology

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

(2012) Michael Horowitz et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes

(2011) Kana Inoue et al.   Cardiovascular Diabetology

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide

(2011) Laszlo Hegedüs et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis

(2009) Daphne P Guh et al.   BMC PUBLIC HEALTH

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

(2009) Prospective Studies Collaboration   LANCET